688319 欧林生物
盘后撮合 08-05 15:00:01
资讯
新帖
简况
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”
证券之星 · 03:48
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”
股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告》
证券之星 · 01:59
股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告》
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”
证券之星 · 07-29
欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”
7月28日欧林生物跌5.02%，科创创新药ETF国泰基金重仓该股
证券之星 · 07-28
7月28日欧林生物跌5.02%，科创创新药ETF国泰基金重仓该股
每周股票复盘：欧林生物（688319）推进重组金葡菌疫苗海外授权
证券之星 · 07-26
每周股票复盘：欧林生物（688319）推进重组金葡菌疫苗海外授权
欧林生物：公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群
证券日报网 · 07-22
欧林生物：公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群
7月20日欧林生物跌14.37%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-20
7月20日欧林生物跌14.37%，兴全社会价值三年持有混合基金重仓该股
7月17日欧林生物跌8.04%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-17
7月17日欧林生物跌8.04%，兴全社会价值三年持有混合基金重仓该股
欧林生物(688319.SH)：网传的《重组金葡菌疫苗(rFSAV)Ⅲ期临床数据审计报告》采用的数据及其结论均与公司临床试验实际情况不符
智通财经 · 07-17
欧林生物(688319.SH)：网传的《重组金葡菌疫苗(rFSAV)Ⅲ期临床数据审计报告》采用的数据及其结论均与公司临床试验实际情况不符
7月16日欧林生物跌13.34%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-16
7月16日欧林生物跌13.34%，兴全社会价值三年持有混合基金重仓该股
欧林生物：重组金葡菌疫苗Ⅲ期临床保护效力为73.25%
证券之星 · 07-15
欧林生物：重组金葡菌疫苗Ⅲ期临床保护效力为73.25%
7月13日欧林生物（688319）龙虎榜数据：机构净买入2.76亿元，北向资金净卖出9455.17万元
证券之星 · 07-13
7月13日欧林生物（688319）龙虎榜数据：机构净买入2.76亿元，北向资金净卖出9455.17万元
7月13日欧林生物跌19.56%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-13
7月13日欧林生物跌19.56%，兴全社会价值三年持有混合基金重仓该股
每周股票复盘：欧林生物（688319）获国家技术发明奖二等奖
证券之星 · 07-12
每周股票复盘：欧林生物（688319）获国家技术发明奖二等奖
7月10日欧林生物涨11.54%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-10
7月10日欧林生物涨11.54%，兴全社会价值三年持有混合基金重仓该股
欧林生物（688319）披露荣获2025年度国家技术发明奖二等奖公告，7月8日股价下跌5.38%
证券之星 · 07-08
欧林生物（688319）披露荣获2025年度国家技术发明奖二等奖公告，7月8日股价下跌5.38%
7月8日欧林生物跌5.38%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 07-08
7月8日欧林生物跌5.38%，兴全社会价值三年持有混合基金重仓该股
欧林生物开启招股：第一季营收1.6亿 大股东上海武山去年套现2.8亿
雷递网 · 07-04
欧林生物开启招股：第一季营收1.6亿 大股东上海武山去年套现2.8亿
欧林生物（688319）披露重新递交H股上市申请公告，7月1日股价下跌12.23%
证券之星 · 07-01
欧林生物（688319）披露重新递交H股上市申请公告，7月1日股价下跌12.23%
欧林生物(688319.SH)重新向香港联交所递交H股发行上市申请并刊发申请资料
智通财经 · 07-01
欧林生物(688319.SH)重新向香港联交所递交H股发行上市申请并刊发申请资料
加载更多
公司概况
公司名称：
成都欧林生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-08
主营业务：
成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗。
发行价格：
9.88
{"stockData":{"symbol":"688319","market":"SH","secType":"STK","nameCN":"欧林生物","latestPrice":24.5,"timestamp":1785913201000,"preClose":23.28,"halted":0,"volume":8777583,"delay":0,"changeRate":0.0524,"floatShares":405000000,"shares":405000000,"eps":0.1395,"marketStatus":"盘后撮合","change":1.22,"latestTime":"08-05 15:00:01","open":23.49,"high":24.68,"low":23.26,"amount":213000000,"amplitude":0.061,"askPrice":24.5,"askSize":21,"bidPrice":24.49,"bidSize":30,"shortable":0,"etf":0,"ttmEps":0.1395,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785979800000},"marketStatusCode":7,"adr":0,"adjPreClose":23.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785893400000,1785900600000],[1785906000000,1785913200000]],"highLimit":25.61,"lowLimit":20.95,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":405409300,"isCdr":false,"pbRate":10.14,"roa":"--","peRate":175.62724,"roe":"2.96%","epsLYR":0.0549,"committee":-0.259669,"marketValue":9933000000,"turnoverRate":0.0217,"status":0,"floatMarketCap":9933000000},"requestUrl":"/m/hq/s/688319","defaultTab":"news","newsList":[{"id":"2657566165","title":"欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657566165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2657566165?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:48","pubTimestamp":1785872938,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示欧林生物新获得一项发明专利授权，专利名为“一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用”，专利申请号为CN202411986210.2，授权日为2026年8月4日。本发明提供的一种同时检测复合佐剂/含有复合佐剂产品中佐剂主要成分含量的方法及应用，解决了现有技术检测二油酰基磷脂酰胆碱和胆固醇含量，以及皂树皂苷QS21含量需要两种不同方法进行两次检测的技术问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500005135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756312","title":"股市必读：欧林生物新发布《成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2657756312?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:59","pubTimestamp":1785866349,"startTime":"0","endTime":"0","summary":"公司公告汇总成都欧林生物科技股份有限公司关于持股5%以上股东部分股份解除质押的公告成都欧林生物科技股份有限公司股东泰昌集团有限公司持有公司股份25,893,040股，占公司总股本的6.39%。本次解除质押股份数量为4,000,000股，解除质押后累计质押股份15,410,000股，占其持股总数的59.51%，占公司总股本的3.80%。公司于2026年8月4日收到泰昌集团关于部分股份解除质押的通知函，相关手续已办理完毕。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882485","title":"欧林生物获得发明专利授权：“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655882485?lang=zh_cn&edition=full","pubTime":"2026-07-29 03:32","pubTimestamp":1785267164,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示欧林生物新获得一项发明专利授权，专利名为“一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂和类脂含量的方法及应用”，专利申请号为CN202510731018.7，授权日为2026年7月28日。本发明提供的一种同时检测复合佐剂/含有复合佐剂产品中皂苷类免疫增强剂、类脂含量的方法及应用，解决了现有技术检测复合佐剂中皂苷类免疫增强剂和类脂含量需要至少两种不同方法进行至少两次检测的技术问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900003187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077596","title":"7月28日欧林生物跌5.02%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077596","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654077596?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:44","pubTimestamp":1785228267,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日欧林生物跌5.02%创60日新低，收盘报23.25元，换手率3.27%，成交量13.26万手，成交额3.19亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9225，较上一交易日上涨2.56%，近一年下跌7.53%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319","589720"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654522750","title":"每周股票复盘：欧林生物（688319）推进重组金葡菌疫苗海外授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654522750","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654522750?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:51","pubTimestamp":1785001874,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，欧林生物报收于25.63元，较上周的30.41元下跌15.72%。来自机构调研要点：重组金葡菌疫苗第二适应症拟用于压疮预防，预计今年申报临床批件。公司重组金葡菌疫苗则提供了一种预防的手段，对于患者家庭而言，也是减少成员疾病发生、减少医疗费用的有效手段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653696707","title":"欧林生物：公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2653696707","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653696707?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:53","pubTimestamp":1784728380,"startTime":"0","endTime":"0","summary":"证券日报网7月22日讯，欧林生物在接受调研时表示，公司重组金葡菌疫苗目前临床试验适应症为闭合性单一或多发性骨折的骨科手术的金黄色葡萄球菌感染高危人群。选择骨科手术为适应症，一方面是因为骨科手术中金葡菌感染率较高，另一方面是因为骨科手术患者相比之下自身免疫情况较好，有助于临床试验的成功。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-22/doc-iniisxzt1865167.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-22/doc-iniisxzt1865167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BMED","688319","IBBJ","BK0239","IBBQ","159646","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652296803","title":"7月20日欧林生物跌14.37%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652296803","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652296803?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:29","pubTimestamp":1784536148,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日欧林生物跌14.37%创60日新低，收盘报26.04元，换手率4.44%，成交量17.99万手，成交额4.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652059614","title":"7月17日欧林生物跌8.04%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652059614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652059614?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:26","pubTimestamp":1784276814,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日欧林生物跌8.04%，收盘报30.41元，换手率4.73%，成交量19.17万手，成交额5.76亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652747105","title":"欧林生物(688319.SH)：网传的《重组金葡菌疫苗(rFSAV)Ⅲ期临床数据审计报告》采用的数据及其结论均与公司临床试验实际情况不符","url":"https://stock-news.laohu8.com/highlight/detail?id=2652747105","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652747105?lang=zh_cn&edition=full","pubTime":"2026-07-17 12:22","pubTimestamp":1784262160,"startTime":"0","endTime":"0","summary":"智通财金APP讯，欧林生物 发布公告，近日，公司关注到个别网络平台出现关于公司重组金黄色葡萄球菌疫苗Ⅲ期临床试验数据的不实言论。经核实，网传的《重组金葡菌疫苗Ⅲ期临床数据审计报告》采用的数据如确诊病例人数、受试者总数等关键数据及其结论均与公司临床试验实际情况不符。全分析集纳入所有接受试验用药并完成既定手术的受试者，全过程不存在任何受试者的主观剔除。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","688319","BK0239","IBBQ","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651471412","title":"7月16日欧林生物跌13.34%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651471412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651471412?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:19","pubTimestamp":1784189991,"startTime":"0","endTime":"0","summary":"证券之星消息，7月16日欧林生物跌13.34%，收盘报33.07元，换手率4.12%，成交量16.71万手，成交额5.89亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600026056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430092","title":"欧林生物：重组金葡菌疫苗Ⅲ期临床保护效力为73.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651430092?lang=zh_cn&edition=full","pubTime":"2026-07-15 15:36","pubTimestamp":1784100971,"startTime":"0","endTime":"0","summary":"证券之星消息，欧林生物07月15日在投资者关系平台上答复投资者关心的问题。公司已于2026年7月11日披露《关于重组金黄色葡萄球菌疫苗Ⅲ期临床试验揭盲结果的自愿性披露公告》，重组金葡菌疫苗Ⅲ期临床保护效力为73.25%，超过Ⅲ期临床方案设计的预计保护效力指标（60%）。目前公司正全力推进Ⅲ期临床试验总结报告撰写及后续NDA申报准备工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500025073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651183971","title":"7月13日欧林生物（688319）龙虎榜数据：机构净买入2.76亿元，北向资金净卖出9455.17万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651183971","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651183971?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:58","pubTimestamp":1783936695,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月13日公布的交易公开信息显示，欧林生物因有价格涨跌幅限制的日收盘价格跌幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月13日收盘，欧林生物报收于35.7元，下跌19.56%，换手率7.93%，成交量32.14万手，成交额12.52亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入2.76亿元，北向资金合计净卖出9455.17万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300027241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651941251","title":"7月13日欧林生物跌19.56%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651941251","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651941251?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:31","pubTimestamp":1783931479,"startTime":"0","endTime":"0","summary":"证券之星消息，7月13日欧林生物跌19.56%，收盘报35.7元，换手率7.93%，成交量32.14万手，成交额12.52亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650151013","title":"每周股票复盘：欧林生物（688319）获国家技术发明奖二等奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2650151013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650151013?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:50","pubTimestamp":1783792221,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，欧林生物报收于44.38元，较上周的42.72元上涨3.89%。本周，欧林生物7月10日盘中最高价报44.9元，股价触及近一年最高点。公司公告汇总成都欧林生物科技股份有限公司参与完成的“超级细菌疫苗创制关键技术及推广应用”项目荣获2025年度国家技术发明奖二等奖。国家技术发明奖是国家级权威奖项，此次获奖体现公司研发实力，有助于提升公司竞争力和品牌影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183551","title":"7月10日欧林生物涨11.54%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183551?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:22","pubTimestamp":1783671742,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日欧林生物涨11.54%创60日新高，收盘报44.38元，换手率4.82%，成交量19.54万手，成交额8.4亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000028722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649091991","title":"欧林生物（688319）披露荣获2025年度国家技术发明奖二等奖公告，7月8日股价下跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649091991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649091991?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:15","pubTimestamp":1783520122,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，欧林生物报收于39.36元，较前一交易日下跌5.38%，最新总市值为159.57亿元。近日，成都欧林生物科技股份有限公司发布关于荣获2025年度国家技术发明奖二等奖的自愿性披露公告。公告显示，2026年7月8日，2025年度国家科学技术奖励大会在北京召开，公司参与完成的“超级细菌疫苗创制关键技术及推广应用”项目荣获国家技术发明奖二等奖。该项目针对超级细菌感染耐药性问题，历时18年攻关，在细菌疫苗领域实现重大原始创新。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649282969","title":"7月8日欧林生物跌5.38%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649282969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649282969?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:31","pubTimestamp":1783499485,"startTime":"0","endTime":"0","summary":"证券之星消息，7月8日欧林生物跌5.38%，收盘报39.36元，换手率3.28%，成交量13.28万手，成交额5.28亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800029246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648696159","title":"欧林生物开启招股：第一季营收1.6亿 大股东上海武山去年套现2.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2648696159","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648696159?lang=zh_cn&edition=full","pubTime":"2026-07-04 15:32","pubTimestamp":1783150335,"startTime":"0","endTime":"0","summary":"成都欧林生物科技股份有限公司（简称：“欧林生物”）日前递交招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260704/6391877592713170635835791.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260704/6391877592713170635835791.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34272/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688319","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511648","title":"欧林生物（688319）披露重新递交H股上市申请公告，7月1日股价下跌12.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648511648?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:48","pubTimestamp":1782899283,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，欧林生物报收于38.6元，较前一交易日下跌12.23%，最新总市值为156.49亿元。该股当日开盘44.59元，最高44.6元，最低37.58元，成交额达11.34亿元，换手率为7.01%。公告显示，公司已于2026年6月30日向香港联合交易所有限公司重新提交H股发行上市申请，并在港交所网站刊发了申请资料。本次发行上市尚需境内外监管机构批准，存在不确定性。公司将根据进展履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648959075","title":"欧林生物(688319.SH)重新向香港联交所递交H股发行上市申请并刊发申请资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2648959075","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648959075?lang=zh_cn&edition=full","pubTime":"2026-07-01 08:45","pubTimestamp":1782866716,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧林生物(688319.SH)发布公告，公司正在进行申请境外发行股份(H股)并在香港联交所主板挂牌上市的相关工作。根据本次发行上市的时间安排，公司已于2026年6月30日向香港联交所重新提交了本次发行上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。该申请资料为公司按照香港证监会及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新及修订。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688319","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785913346748,"stockEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.4551},{"period":"3month","weight":-0.3256},{"period":"6month","weight":-0.03},{"period":"1year","weight":0.1049},{"period":"ytd","weight":-0.082}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":-0.0547},{"period":"3month","weight":-0.0812},{"period":"6month","weight":-0.0622},{"period":"1year","weight":0.0667},{"period":"ytd","weight":-0.0369}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都欧林生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9522人(较上一季度增加5.88%)","perCapita":"42576股","listingDate":"2021-06-08","address":"四川省成都市郫都区高新区天欣路99号","registeredCapital":"40540万元","survey":" 成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗。","listedPrice":9.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧林生物,688319,欧林生物股票,欧林生物股票老虎,欧林生物股票老虎国际,欧林生物行情,欧林生物股票行情,欧林生物股价,欧林生物股市,欧林生物股票价格,欧林生物股票交易,欧林生物股票购买,欧林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}